Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 6 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

6Total
Not Applicable (1)
P 1 (1)
P 2 (4)

Trial Status

Recruiting3
Not Yet Recruiting2
Active Not Recruiting1

Clinical Trials (6)

Showing 6 of 6 trials
NCT07206849Phase 2Not Yet Recruiting

Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

NCT03919071Phase 2Active Not Recruiting

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

NCT06444412Phase 2Recruiting

An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With Glioma

NCT07644312Phase 2Not Yet Recruiting

Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG

NCT06964737Phase 1Recruiting

Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas

NCT07091864Not ApplicableRecruiting

Continuous Glucose Monitoring for the Management of Hyperglycemia in Patients With Glioblastoma

Showing all 6 trials

Research Network

Activity Timeline